These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19470641)

  • 1. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor.
    Zhang Q; Zhou YF; Zhang CZ; Zhang X; Lu C; Springer TA
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9226-31. PubMed ID: 19470641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain.
    Xu AJ; Springer TA
    J Biol Chem; 2013 Mar; 288(9):6317-24. PubMed ID: 23322777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
    Jenkins PV; Pasi KJ; Perkins SJ
    Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function.
    Luken BM; Winn LY; Emsley J; Lane DA; Crawley JT
    Blood; 2010 Jun; 115(23):4910-3. PubMed ID: 20354169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of type 2A von Willebrand disease investigated by molecular dynamics simulations and experiments.
    Interlandi G; Ling M; Tu AY; Chung DW; Thomas WE
    PLoS One; 2012; 7(10):e45207. PubMed ID: 23110044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.
    Sutherland JJ; O'Brien LA; Lillicrap D; Weaver DF
    J Mol Model; 2004 Aug; 10(4):259-70. PubMed ID: 15322948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor, Jedi knight of the bloodstream.
    Springer TA
    Blood; 2014 Aug; 124(9):1412-25. PubMed ID: 24928861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfolding the A2 domain of von Willebrand factor with the optical trap.
    Ying J; Ling Y; Westfield LA; Sadler JE; Shao JY
    Biophys J; 2010 Apr; 98(8):1685-93. PubMed ID: 20409490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational stability and domain unfolding of the Von Willebrand factor A domains.
    Auton M; Cruz MA; Moake J
    J Mol Biol; 2007 Feb; 366(3):986-1000. PubMed ID: 17187823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.
    Zhang X; Halvorsen K; Zhang CZ; Wong WP; Springer TA
    Science; 2009 Jun; 324(5932):1330-4. PubMed ID: 19498171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Backbone resonance assignments of the A2 domain of mouse von Willebrand factor.
    Morimoto D; Osugi M; Mahana Y; Walinda E; Shirakawa M; Sugase K
    Biomol NMR Assign; 2021 Oct; 15(2):427-431. PubMed ID: 34286417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-linked glycan stabilization of the VWF A2 domain.
    Lynch CJ; Lane DA
    Blood; 2016 Mar; 127(13):1711-8. PubMed ID: 26773038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF.
    Lynch CJ; Lane DA; Luken BM
    Blood; 2014 Apr; 123(16):2585-92. PubMed ID: 24558203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
    Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
    Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology and physics of von Willebrand factor concatamers.
    Springer TA
    J Thromb Haemost; 2011 Jul; 9 Suppl 1(0 1):130-43. PubMed ID: 21781248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib.
    Emsley J; Cruz M; Handin R; Liddington R
    J Biol Chem; 1998 Apr; 273(17):10396-401. PubMed ID: 9553097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.